Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMRT combined with apatinib for inoperable or iodine-refractory thyroid cancer
ChiCTR-OIN-17011812Phase 2Recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Jul 2017
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in thyroid cancer, sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Progression-free survival. Started Jul 2017; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on ChiCTR-OIN-17011812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIN-17011812.